PPD, Inc. and Bend Research, Inc. have entered into a collaboration in the areas of formulation
development, analytical testing and clinical supplies manufacturing to provide pharmaceutical
and biotechnology companies a full range of chemistry, manufacturing and
controls (CMC) development services.
As part of the collaboration, the two companies will refer
potential business opportunities to one another in the areas of compound characterization,
particle engineering, formulation development, clinical trial material (CTM)
manufacturing, analytical development, stability programs, and GMP release and
quality control testing. A key area of collaboration will be inhalation
formulation development and particle engineering for drug therapies. The two
companies also plan to collaborate on opportunities that involve services
provided by each company and to work together on client bids and projects.
Bend Research’s strong formulation development and particle engineering
expertise will strengthen PPD’s ability to provide clients full-service CMC
product development solutions. Through the collaboration, Bend
Research clients will have access to PPD’s state-of-the-art facilities in Madison, Wis., Wayne, Pa., and Athlone, Ireland.
“We continue to see strong global demand for our analytical
laboratory services,” said Magdalena Mejillano, Ph.D., vice president of
cGMP lab services for PPD. “The agreement with Bend Research allows us to expand
our preformulation and formulation development expertise, enhance our strong
CMC laboratory capabilities and provide clients a more complete offering for
small and large molecule testing.” Rod Ray, Ph.D., Bend Research president
and CEO, added, “Working with PPD strengthens our position as a leading
drug formulation resource for pharmaceutical companies. This collaboration with
PPD offers a competitive advantage to biopharmaceutical companies looking for innovative
drug delivery technologies.”
